 The European Commission EC has approved FibroGen Inc NASDAQ: FGEN and Astellas Pharmas OTC: ALPMF Evrenzo roxadustat for anemia caused by chronic kidney disease CKD, just days after the FDA turned down the drug. Related: FDA Shoots Down Roxadustat Application, Asks For Additional Trial. 